Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats

被引:17
作者
Kim, YC
Shim, HJ
Lee, JH
Kim, SH
Kwon, JW
Kim, WB
Lee, MG
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea
[3] Dong A Pharmaceut Co, Res Lab, Yongin, South Korea
关键词
DA-8159; DA-8164; enzyme inducers and inhibitors; CYP isozymes; pharmacokinetics; rats;
D O I
10.1002/bdd.453
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In order to find what types of hepatic microsomal cytochrome P450 (CYP) isozymes are involved in the metabolism of DA-8159 and in the formation of DA-8164 in rats, enzyme inducers, such as dexamethasone, phenobarbital, 3-methylcholanthrene and isoniazid, and enzyme inhibitors, such as troleandomycin and quinine, were pretreated in rats. After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 mu g min/ml) and DA-8164 (98.0 versus 79.8 mu g min/ml) were significantly smaller and greater, respectively, than those in control rats. However, the AUC values of DA-8159 were not significantly different after pretreatment with phenobarbital, isoniazid and 3-methylcholanthrene (main inducers of CYP2B1/2, 2E1 and 1A1/2, respectively, in rats). In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 mu g min/ml) and DA-8164 (34.8 versus 76.5 mu g min/ml) were significantly greater and smaller, respectively However, in rats pretreated with quinine (a main inhibitor of CYP2D1 in rats), the AUC of DA-8159 was comparable to that in control rats. The above data indicate that DA-8159 was metabolized and DA-8164 was formed mainly via CYP3A1/2 in rats. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 50 条
  • [21] Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats
    Bu, SC
    Kim, YG
    Kim, SH
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (04) : 157 - 164
  • [22] Erectile potentials of a new phosphodiesterase type 5 inhibitor, DA-8159, in diet-induced obese rats
    Yu, JY
    Kang, KK
    Yoo, M
    ASIAN JOURNAL OF ANDROLOGY, 2006, 8 (03) : 325 - 329
  • [23] Solid state of a new PDE-5 inhibitor DA-8159: Characterization, dissolution, transformation
    Ji Yoon Ryu
    Young-Taek Sohn
    Archives of Pharmacal Research, 2012, 35 : 861 - 866
  • [24] Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique
    Shim, HJ
    Lee, EJ
    Kim, SH
    Kim, SH
    Yoo, M
    Kwon, JW
    Kim, WB
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (07) : 285 - 291
  • [25] DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats
    Kang, KK
    Ahn, GJ
    Sohn, YS
    Ahn, BO
    Kim, WB
    ARCHIVES OF PHARMACAL RESEARCH, 2003, 26 (08) : 612 - 619
  • [26] DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats
    Kyung Koo Kang
    Gook Jun Ahn
    Yong Sung Sohn
    Byoung Ok Ahn
    Won Bae Kim
    Archives of Pharmacal Research, 2003, 26 : 612 - 619
  • [27] Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats
    Shim, HJ
    Kim, YC
    Jang, JM
    Park, KJ
    Kim, DH
    Kang, KK
    Ahn, BO
    Kwon, JW
    Kim, WB
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (09) : 409 - 418
  • [28] Solid state of a new PDE-5 inhibitor DA-8159: Characterization, dissolution, transformation
    Ryu, Ji Yoon
    Sohn, Young-Taek
    ARCHIVES OF PHARMACAL RESEARCH, 2012, 35 (05) : 861 - 866
  • [29] Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography
    Shim, HJ
    Lee, EJ
    Jung, YH
    Kim, SH
    Kim, SH
    Yoo, M
    Kwon, JW
    Kim, WB
    Lee, MG
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (03) : 527 - 533
  • [30] Dose-dependent Pharmacokinetics and First-pass Effects of Mirodenafil, a New Erectogenic, in Rats
    Choi, Young H.
    Lee, Young S.
    Bae, Soo H.
    Kim, Tae K.
    Lee, Bong-Y.
    Lee, Myung G.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (06) : 305 - 317